Redeye comments on OncoZenge’s announcement of a SEK7.5m convertible loan agreement with major shareholder Linc. We view this as a strategic move that enhances the company’s financial flexibility ahead of the pivotal phase III trial for BupiZenge, further reinforcing recent momentum in funding and partnership execution.
LÄS MER